CAD system identifies abnormalities in breast sonograms
Cedara Software is developing a computer-assisted detection system for breast ultrasound. The software, announced as a work-in-progress at the RSNA meeting, is intended to identify the sonographic characteristics of benign as well as malignant breast masses and to classify the extent of malignancy for specific nodules.
Cedara Software is developing a computer-assisted detection system for breast ultrasound. The software, announced as a work-in-progress at the RSNA meeting, is intended to identify the sonographic characteristics of benign as well as malignant breast masses and to classify the extent of malignancy for specific nodules.
The company is evolving four configurations of the breast CAD system, which require FDA approval before commercialization in the U.S. B-CAD will identify features of user-defined lesions that correspond to the BI-RADS lexicon in ultrasound images. B-CAD Plus, in addition to flagging user-defined breast lesions, will use sonographic characteristics to compute the probability of malignancy. B-CAD Pro will identify breast lesions and their features. B-CAD Live will provide all the features of the other CAD options in real-time.
The Cedara B-CAD technology was based on the analysis of more than 1400 images and data from patients with healthy breast tissue, as well as cases with known clinical outcomes following the diagnosis of a breast malignancy.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Contrast-Enhanced Mammography Study Reveals 24 Percent Lower Sensitivity with Moderate/Marked BPE
April 30th 2025In comparison to minimal or mild background parenchymal enhancement on contrast-enhanced mammography (CEM), researchers found that moderate or marked BPE was associated with a 12 percent lower AUC for breast cancer detection.
